Incretin-based drugs and the risk of congestive heart failure

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 277-284

  Yu, Oriana Hoi Yun ^a,b   Filion, Kristian B ^a,c   Azoulay, Laurent ^a,c   Patenaude, Valerie ^a   Majdan, Agnieszka ^b   Suissa, Samy ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN DERIVATIVE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INCRETIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE DURATION; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED KINGDOM; VERY ELDERLY; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHY; EPIDEMIOLOGY; HEART FAILURE; MIDDLE AGED;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EPIDEMIOLOGIC METHODS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED;

EID: 84921933782     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1459     Document Type: Article

References (30)

1. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002;122:531-544
2. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
3. Johnsen EJ. Takeda Presents Additional Results from EXAMINE Cardiovascular Safety Outcomes Trial at the 49th Annual Meeting of the European Association for the Study of Diabetes. Presented at the 49th Annual Meeting of the European Association for the Study of Diabetes, 23-27 September 2013, Barcelona, Spain. Available from http://www.tpi.takeda.com/media/news-releases/2013/additional-resultsfromexamine-cardiovascular-safety-outcomestrialpresented-at-easd/. Accessed 25 August 2014
4. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55, 141 participants. Cardiovasc Ther 2014;32:147-158
5. Hattori A, Kawamura I, Yamada Y, et al. Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a crosssectional study. BMJ Open 2013;3:e003201
6. García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425
7. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-689
8. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304
9. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591-596
10. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
11. Burns EM, Rigby E, Mamidanna R, et al. Systematic review of discharge coding accuracy. J Public Health (Oxf) 2012;34:138-148
12. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-590
13. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5
14. Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013;126(Suppl. 1):S10-S20
15. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-1619
16. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135
17. Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U. K. primary care setting. Diabetes Care 2005;28:20-26
18. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested casecontrol study. BMJ 2012;344:e3645
19. Abdelmoneim AS, Eurich DT, Gamble JM, Simpson SH. Use patterns of antidiabetic regimens by patients with type 2 diabetes. Can J Diab 2013;37:394-400
20. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
21. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 2009;20:488-495
22. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699
23. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965
24. Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006;21:208-214
25. Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diab Med 2008;25:1129-1131
26. Bergenstal RM, Wysham C, Macconell L, et al.; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-439
27. Halbirk M, Nørrelund H, Møller N, et al. Cardiovascular and metabolic effects of 48-h glucagonlike peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1096-H1102
28. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 25 June 2014 [Epub ahead of print]
29. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J General Pract 2010;60:e128-e136
30. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412